<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="50194">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01799629</url>
  </required_header>
  <id_info>
    <org_study_id>2121 110</org_study_id>
    <nct_id>NCT01799629</nct_id>
  </id_info>
  <brief_title>Efficacy of Prophylactic Glycerin Suppositories for Feeding Intolerance in Very Low Birth Weight Preterm Infants: a Randomized Trial</brief_title>
  <official_title>Efficacy of Prophylactic Glycerin Suppositories for Feeding Intolerance in Very Low Birth Weight Preterm Infants: a Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>King Faisal Specialist Hospital &amp; Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dr. Sulaiman Alhabib Medical City, Riyadh</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>King Faisal Specialist Hospital &amp; Research Center</source>
  <oversight_info>
    <authority>Saudi Arabia: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy of prophylactic glycerin suppositories will accelerate the
      elimination of meconium from the large intestine and thus reduce the incidence of feeding
      intolerance in very low birth weight (VLBW) infants
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>days to achieve full tolerated feeding (breast milk or formula) by NGT or by mouth (140cc/kg/day)</measure>
    <time_frame>2years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of feeding intolerance</measure>
    <time_frame>2years</time_frame>
    <safety_issue>No</safety_issue>
    <description>which is defined by the presence of GRVs &gt; 50 % of the previous feed for two consecutive feeds in addition to two of the following: I.	Abdominal distention &gt; 1 cm in 12 hour. II.	Abdominal tenderness. III.	Vomiting. IV.	Bile stained aspirate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of necrotizing enterocolitis (NEC)</measure>
    <time_frame>2years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Infant, Very Low Birth Weight</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention group will receive the glycerin suppository</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Normal care</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glycerin suppositories</intervention_name>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Preterm infants with birth weight &lt; 1250g.

          2. Inborn or outborn infants

          3. Less than 72 hours of age.

        Exclusion Criteria:

          1. Congenital malformations.

          2. Acute abdomen needing surgical intervention.

          3. Severity of illness such that death is likely in the first few days after birth.

          4. Inability to get the parental consent.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>1 Month</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emad M Khadawardi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>King Faisal Specialist Hospital &amp; Research Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>King Faisal Specialist Hospital &amp; Research Centre</name>
      <address>
        <city>Riyadh</city>
        <zip>11211</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eamd m Khadawardi, MD</last_name>
      <phone>00966505541843</phone>
      <email>ekhadawardi@kfshrc.edu.sa</email>
    </contact>
    <investigator>
      <last_name>Emad m Khadawardi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jasim Anabrees, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Khalid Al-Faleh, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eyad M Almidani</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sulaiman Al habib Medical Center</name>
      <address>
        <city>Riyadh</city>
        <country>Saudi Arabia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jasim Anabrees, MD</last_name>
      <phone>00966590591102</phone>
      <email>jasim1800@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Jasim Anabrees, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Saudi Arabia</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>April 11, 2013</lastchanged_date>
  <firstreceived_date>February 25, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>King Faisal Specialist Hospital &amp; Research Center</investigator_affiliation>
    <investigator_full_name>Emad Mohammad Khadawardi</investigator_full_name>
    <investigator_title>Consultant Neonatology</investigator_title>
  </responsible_party>
  <keyword>Glycerin suppositories</keyword>
  <keyword>Feeding intolerance</keyword>
  <keyword>preterm infants</keyword>
  <keyword>prophylactic use</keyword>
  <keyword>elimination of meconium</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Birth Weight</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glycerol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
